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Abstract 
 
The purpose of the present investigation was to determine the feasibility of using 
lysolipid-based thermal sensitive liposomes (145 nm) for high molecular weight molecule 
delivery.  Fluorescein isothiocyanate conjugate-albumin was used as a model drug (MW 
66 kDa). Thermal sensitive liposomes, which encapsulated the protein were prepared 
using a passive encapsulation methodology involving freeze-thawing cycles followed by 
extrusion. In vitro release studies at various temperatures indicated rapid release 
behaviour of the encapsulated protein at 42 and 44.5 oC but a good stability at 37.5 oC. 
The current findings suggest that lysolipid-based thermal sensitive liposomes can be used 
to deliver high molecular weight molecules.  
 
Keywords: lysolipid incorporated thermal sensitive liposome; macromolecular 
therapeutics; mild-hyperthermia. 
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Unilamellar liposomes are artificial bilayer vesicles composed mainly of a mixture of 
phospholipids that possess a hydrophilic interior (Drummond et al., 1999). Using bilayer 
structures as a barrier, it has been shown that hydrophilic drugs can be encapsulated into 
the interior of liposomes to prevent undesirable in vivo exposure (Allen and Chonn., 
1987). Since the first application of liposomes as a potential therapeutic delivery system 
(Bangham.,1978), extensive formulation studies have been carried out to grant liposomes 
the ability to deliver encapsulated therapeutic agents to targeted areas, with minimum 
premature release (Allen et al., 1991; Charrois and Allen., 2003). Thermally-sensitive 
liposomes enable a liposome-based drug delivery system that is capable of releasing 
encapsulated drug in response to elevation of temperature to the mild-hyperthermia range, 
whilst preventing premature leakage of encapsulated drug at 37.5 oC (Banno et al., 2010). 
 
Lysolipids are a type of phospholipid that contain only one, rather than two, hydrocarbon 
chains. Such lipids, when mixed with normal phospholipids can lower the phase 
transition temperature of the lipid bilayer to the mild hyperthermia range. Thus lysolipid 
incorporated thermal sensitive liposomes (LTSL) are the most widely studied and applied 
formulation among various types of thermally sensitive liposomes. Upon heating, liquid–
solid boundaries start to form in the lipid bilayer and lysolipids have been reported to 
create and stabilize hydrophilic water pores along these highly compressible liquid–solid 
boundaries, which significantly enhances the permeability of liposome (Needham et al., 
2001). ThermoDox® is a doxorubicin-encapsulated LTSL that consists of 1-palmitoyl-2-
hydroxy-sn-glycero-3-phosphocholine (MSPC),1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[methoxy(polyethylene,glycol)-2000 (PEG.DSPE.2000) and 1,2-
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dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in 10:4:90 molar ratio (Poon and 
Borys., 2009). This commercialized formulation has been reported to completely release 
the encapsulated doxorubicin within 30 seconds at 42 oC (Mills and Needham., 2005).   
 
However, the application of LTSL has so far been restricted to low MW therapeutic 
agents, such as doxorubicin for cancer therapy. The aim of this note is to demonstrate the 
potential of using LTSL to carry and release high MW molecules, such as proteins.  
Fluorescein isothiocyanate conjugate-albumin (FITC-BSA) was used as a model protein- 
based drug.  The liposome membrane formulation used in this study is similar to that of 
ThermoDox®. This will not only expand the potential applications of LTSL, but also 
provide indications of the maximum size and/or the stability of water pores that lysolipids 
are able to form upon heating. 
 
FITC-BSA encapsulated LTSL liposomes were prepared using a passive encapsulation 
methodology followed by extrusion. Generally, stock lipid chloroform solutions were 
mixed (DPPC, MSPC and PEG.DSPE.2000 at 90:10:4 molar ratio) and solvent was then 
removed using a rotary evaporator to form a dried thin layer. The dried lipid film was 
hydrated using FITC-BSA (60 mg/ml) containing HEPES buffer (20 mM HEPES, 150 
mM NaCl, pH 7). 5 freeze-thawing cycles were applied during the hydration process, 
with the temperature during the thawing step being carefully selected (50 oC) in order to 
avoid irreversible conformational alteration to the secondary structure of the protein 
(Griebenow et al., 1995). The liposome formulation was then extruded through a 100 nm 
filter to reduce the size of the liposomes. FITC-BSA encapsulating LTSL were then 
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separated from any unencapsulated protein on a Sepharose CL-2B column (0.8 cm × 10 
cm) equilibrated with HEPES buffer (Barenholz et al., 1977). The encapsulation 
efficiency was determined by comparing the fluorescent intensity difference prior to and 
after the lysis of liposome using aqueous 1 v/v % Triton X100 (emission wavelength at 
520 nm excitation wavelength at 490 nm).  
 
The thermal sensitivity of FITC-BSA encapsulated LTSL was determined by observing 
the release behavior of encapsulated protein at various temperatures (Mills and Needham, 
2006). HEPES buffer (5 ml) in a plastic tube was heated to a desired temperature using 
water bath. Liposome solution (500 µl) was then introduced into the temperature 
equilibrated buffer solution and taken out at preset time points. The sample was then 
quickly transferred into an ice bath to prevent subsequent release.  The temperature of all 
samples was allowed to equilibrate with room temperature (20±2 oC).  The fluorescent 
intensities of samples were then measured to determine the release behaviour of 
encapsulated protein molecules (emission wavelength at 520 nm, excitation wavelength 
at 490 nm).  
 
The particle size of liposome was measured using photon correlation spectroscopy and 
found to be 145 nm. The lipid to protein ratio of the liposome (weight to weight ratio) 
was 156:1. 72% of protein molecules were found to be firmly associated with the lipid 
membrane (i.e. in the form of transmembrane protein). The rest of the protein molecules 
were encapsulated in the interior core of liposomes. Little change in protein conformation 
(i.e. proportion of α helix,  β sheet and random coil ) is expected  during the thawing (i.e. 
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50 0C for 20 min) and freeze process based on the stability studies reported by others (e.g. 
Griebenow and Klibanov., 1995;  Lin and Koenig., 1976).  
 
The release behaviour of FITC-BSA encapsulated LTSL at various temperatures are 
shown in Figure 1.  As can be seen, the liposomes demonstrated not only impressive 
stability at 37.5 oC, but also a rapid release behaviour at 42 and 44.5 oC.  
 
In order to determine the necessity of the incorporation of lysolipid, the release behaviour 
of FITC-BSA encapsulated liposome without the incorporation of MSPC (DPPC, and 
DSPE.PEG2000 at 90:10 molar ratio) was investigated. Release study indicated that 
lysolipid-free vesicles were unable to release encapsulated protein at either 42 or 48 oC 
(data not shown).  
 
It is interesting to note that the nature of the high molecular weight molecules might have 
an important influence on their release rate.  Preliminary experiments using dextran (MW 
40 kDa) indicated a much slower release at the phase transition temperature of the vesicle 
(i.e. 42oC). This may be related to the different conformations of dextran and albumin.  
 
In summary, our results have demonstrated that lysolipid based thermally sensitive 
liposomes are able to release high MW hydrophilic protein molecules upon temperature 
rise. In the near future, optimization of the formulation will be carried out to accelerate its 
release rate in a mild-hyperthermia temperature range. The preparation procedure will 
also be optimized in order to enhance the encapsulation efficiency of the protein.   
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Figure legend:  
Fig. 1. Release behavior of FITC-BSC encapsulated LTSL at 48, 44.5, 42, 39 and 37.5 oC 
respectively (n=3).  
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